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Dear Editor,  
                   After reading the article by Bernhardt et al.1, we would like to share our experience from 
one of the European regions most affected by the SARS-CoV-2. Our hospital’s neuro-oncological 
outpatient clinic is a tertiary center for brain tumor patients, with a regular workload of 15 
patients/week. 
Since the SARS-CoV-2 outbreak reached the pandemic status, our hospital was identified as a COVID-
19 referral center. Complete closure of non-urgent hospital activities followed. Non-deferrable 
oncological pathologies were among the only exceptions following the re-arrangement2.  
Within the framework of the emergent plan re-organizing the regional health-care system, we were 
able to operate 3-4 patients with brain tumors per week and to guarantee neuro-oncological visits 
three times per week.  
From March 8th to April 30th, 124 follow-up patients were evaluated: 67, 27, 15, and 3 subjects had 
previous surgery for High- and Low-Grade Gliomas (HGGs, LGGs), meningiomas, and cerebral 
metastases, respectively; 12 further patients were evaluated for surgery. We also provided 20 
neuro-oncological evaluations to other clinics.  
Nine planned visits were rescheduled: 3 LGG patients declared to fear a possible COVID-19 infection 
in a nosocomial environment; 1 LGG patient could not perform the follow-up MRI; 5 patients (one 
with LGG, three with meningiomas and one long-survivor with HGG) underwent the prescribed MRI 
and were evaluated remotely via image-transfer and telephone interview due to their general good 
condition. 
During the outpatient activity, a policy was deployed to mitigate the risk of exposure of  patients and 
further dissemination of COVID-19. Health-care providers and patients followed the hospital 
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guidelines that were drafted accordingly to those the World Health Organization released3. Patients 
underwent a telephone interview 1-2 days before the scheduled appointment to rule out the 
presence of respiratory signs, symptoms or fever. Before entering into the building, patients crossed 
a check-point, where a trained operator measured the body temperature with a contactless digital 
thermometer. Subjects were only allowed into the building with a temperature ≤ 37.4° C. No visitors 
were allowed aside a caregiver for patients who required one. We wore personal protective 
equipment4 and extended the regular visit time to avoid gatherings in the waiting room. When 
feasible, we made the medical examination follow the MRI on the same day, to reduce the flow of 
patients accessing the unit. 
Two of our patients are examples of why it is crucial to avoid COVID-19 in neuro-oncological 
subjects. They were 73 and 69 years old, with a KPS of 50-60 and multiple comorbidities. They 
underwent surgery for HGG in November 2019 and concomitant radiotherapy and chemotherapy; 
they were hospitalized in a rehabilitation unit, where they acquired SARS-CoV-2 pneumonia. They 
were then transferred to a COVID-19 unit where they deceased three weeks later.  
As a further measure to limit the patients’ accesses to the outpatient clinic, we encouraged the use 
of e-mails, telephone, and image-transfer tools to provide continuity of care. We enhanced our 
multidisciplinary network, with remote consultations and video-conferences, to better share the 
management of the patients among surgeons, oncologists, radiotherapists and other specialists as 
needed. Despite the objective difficulties created by the pandemic, we provided an efficient service, 
while avoiding referrals of symptomatic patients to the emergency ward. Our approach improved 
patients’ safety since hospital exposures were limited, while addressing oncological needs. No 
patient was infected in the outpatient clinic. Our experience contributes to the management 
proposed by Bernhardt, without compromising the standard of care. Such a multidisciplinary effort 
may enhance our response to the pandemic and contribute to the development of shared guidelines 
for modifying the approach to patients’ follow-up, as it is already emerging in other medical fields5. 
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We will live with the virus for the months to come. As physicians, we will be asked to improve the 
tools -such as telemedicine or image-transfer methods- we use to evaluate and communicate with 
our patients in the era of physical distancing6. 
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